Peter K. S. Siegl, PhD
Peter Siegl has extensive experience in drug discovery and development from his 27-year tenure at Merck, 10 years consulting (biotech, pharma and venture capital organizations) as well as contributions to external scientific and regulatory landscape. He is the author of more than 125 scientific publications in peer reviewed journals. Pete is a founder and was first president of the Safety Pharmacology Society (2001), chaired the ILSI/Health and Environmental Science Institute Cardiovascular Safety Subcommittee (2002-2006), was Deputy Topic Leader representing PhRMA on the International Conference on Harmonization: Topic ICH S7B, (guideline for assessing risk for QT interval prolongation) and was Safety Pharmacology Technical Group Co-Leader in the PhRMA DruSafe Committee (2000-2007). Recently (2010-2016), he served on the External Scientific Advisory Board for Medicines for Malaria Venture. Currently Pete is an independent consultant providing scientific leadership for novel drug discovery and nonclinical development programs, focusing on strategic risk assessments to increase probabilities of success.